首页> 外文期刊>OncoTargets and therapy >Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment
【24h】

Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment

机译:三药诱导化疗加根治性局部治疗的局部晚期非小细胞肺癌患者的放射反应和生存率

获取原文
           

摘要

Objectives: If concurrent chemoradiotherapy cannot be performed, induction chemotherapy followed by radical-intent surgical treatment is an acceptable option for non primarily resectable non-small-cell lung cancers (NSCLCs). No markers are available to predict which patients may benefit from local treatment after induction. This exploratory study aims to assess the feasibility and the activity of multimodality treatment, including triple-agent chemotherapy followed by radical surgery and/or radiotherapy in locally advanced NSCLCs. Methods: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m2, d1), and gemcitabine (1,000 mg/m2 d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. We analyzed radiological response and toxicity. Estimated progression-free survival (PFS) and overall survival (OS) were correlated to response, surgery, and clinical features. Results: In all, 58 NSCLCs were included in the study: 40 staged as IIIA, 18 as IIIB (according to TNM Classification of Malignant Tumors–7th edition staging system). A total of 36 (62%) patients achieved partial response (PR), and six (10%) progressions were recorded. Grade 3–4 hematological toxicity was observed in 36 (62%) cases. After chemotherapy, 37 (64%) patients underwent surgery followed by adjuvant radiotherapy, and two patients received radical-intent radiotherapy. The median PFS and OS were 11?months and 23?months, respectively. Both PFS and OS were significantly correlated to objective response ( P <0.0001) and surgery ( P <0.0001 and P =0.002). Patients obtaining PR and receiving local treatment achieved a median PFS and OS of 35 and 48 months, respectively. Median PFS and OS of patients not achieving PR or not receiving local treatment were 5–7 and 11–15 months, respectively. The extension of surgery did not affect the outcome. Conclusion: The multimodality treatment was feasible, and triple-agent induction was associated with a considerable rate of PR. Patients achieving PR and receiving radical surgery or radiotherapy (53%) achieved a median OS of 4 years.
机译:目的:如果不能同时进行放化疗,对于非主要可切除的非小细胞肺癌(NSCLC),诱导化疗后再行根治性手术治疗是可接受的选择。没有标记可用于预测诱导后哪些患者可从局部治疗中受益。这项探索性研究旨在评估多模式治疗的可行性和活性,包括在局部晚期NSCLC中进行三药化疗,然后进行根治性手术和/或放疗。方法:我们回顾性收集了接受卡铂(曲线下6 d [d] 1天),紫杉醇(200 mg / m 2 ,d1)和吉西他滨诱导化疗的局部晚期NSCLCs的数据(1,000 mg / m 2 d1,8)进行三到四个疗程,然后进行根治性手术和/或放疗。我们分析了放射反应和毒性。估计的无进展生存期(PFS)和总体生存期(OS)与反应,手术和临床特征相关。结果:总共纳入了58例NSCLC:40例为IIIA分期,18例为IIIB分期(根据TNM第7版恶性肿瘤分期系统)。共有36位患者(62%)达到了部分缓解(PR),并记录了6位患者(10%)的进展。在36例(62%)病例中观察到3-4级血液学毒性。化疗后,有37名患者(64%)接受了外科手术,然后进行了辅助放疗,其中两名患者接受了根治性放疗。 PFS和OS的中位数分别为11个月和23个月。 PFS和OS均与客观反应(P <0.0001)和手术(P <0.0001,P = 0.002)显着相关。获得PR并接受局部治疗的患者的PFS和OS中位数分别为35个月和48个月。未达到PR或未接受局部治疗的患者的中位PFS和OS分别为5-7个月和11-15个月。手术时间延长不影响预后。结论:多模式治疗是可行的,三药诱导与较高的PR率相关。获得PR并接受根治性手术或放疗的患者(53%)的中位OS为4年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号